Reducingunnecessaryantibiotics,onetestatatime
Altera Diagnostics is the authorized U.S. distributor of FebriDx — bringing precision rapid diagnostics to the clinicians who need them most.
Empoweringclinicianswithdiagnosticclarity
Acute respiratory infections are the most common reason patients visit urgent care and emergency departments. Yet the majority are viral — and don't require antibiotics. The challenge is that bacterial and viral symptoms look nearly identical.
This diagnostic uncertainty drives massive antibiotic overprescription — contributing to 2.8 million resistant infections and over 35,000 deaths annually in the U.S. alone.
We exist to close that gap. By distributing FebriDx — the first rapid, instrument-free test that differentiates bacterial from non-bacterial infections at the point of care — we give clinicians the confidence to prescribe the right treatment, every time.
Whatdrivesus
Precision over guesswork
We believe clinicians deserve objective data — not intuition alone — when deciding whether to prescribe antibiotics.
Speed at the point of care
Diagnostic answers should come during the patient visit, not days later. 10 minutes changes everything.
Stewardship as a mandate
Every unnecessary antibiotic prescription accelerates resistance. We're committed to giving providers the tools to prescribe responsibly.
Partnership, not just supply
We don't just ship test kits. We train your staff, support your billing, and stand behind your implementation.
Ourjourney
FebriDx U.S. clinical trial begins — 20 sites, 520+ ARI patients enrolled
JAMA Network Open publishes clinical trial results — 93.2% sensitivity, 99% NPV
FDA 510(k) clearance granted for FebriDx in the United States
FDA CLIA waiver secured — unlocking broad U.S. market access for point-of-care use
CMS establishes $41.38 reimbursement rate under CPT code PLA 0442U
Altera Diagnostics launches as authorized U.S. distributor of FebriDx
ReadytobringFebriDxtoyourpractice?
Talk to our team about volume pricing, onboarding, and clinical support.